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The accumulation of mutant protein is a common feature of neurodegenerative disease. 
In Huntington’s disease, a polyglutamine expansion in the huntingtin protein triggers 
neuronal toxicity. Accompanying neuronal death, mutant huntingtin aggregates in large 
macromolecular structures called inclusion bodies. The function of the machinery for 
intracellular protein degradation is linked to huntingtin toxicity and components of this 
machinery colocalize with inclusion bodies. An increasing body of evidence implicates 
the ubiquitin-proteasome pathway in the failure of cells to degrade mutant huntingtin. A 
number of potential mechanisms that link compromised ubiquitin-proteasome pathway 
function and neurodegeneration have been proposed and may offer opportunities for 
therapeutic intervention. 
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THE BURDEN OF NEURODEGENERATIVE DISEASE 
Neurodegenerative disease is the sixth leading killer in the U.S. Alzheimer’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, and Huntington’s disease (HD) all affect different regions of the brain and 
have heterogeneous clinical presentations. However, each increases in incidence with age, affects the 
nervous system, and inexorably leads to death. Each is also characterized by accumulation of misfolded 
mutant protein. Among them, only HD is predominantly inherited, with a single gene at the root of the 
disease. As in the case of other neurodegenerative diseases, there is no cure for HD, nor is there any 
treatment that slows progression.  
HUNTINGTON’S DISEASE 
HD is estimated to affect five to seven in 100,000 people, although up to 90% fewer are affected in Asian 
and African populations[1]. While HD most often presents in the fourth or fifth decade of life, the onset 
of disease has been documented from ages of 1 through 80 years, with changes in personality, motor 
control, and cognition[2,3]. At the time of clinical diagnosis, most patients demonstrate chorea or 
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dystonia and rigidity, a lack of coordination, saccadic eye movements, and an inability to voluntarily 
maintain muscle tone[1].  
HD belongs to a family of nine diseases caused by an expansion of a stretch of CAG repeats in the 
coding region of a gene. The effect of the CAG repeat expansion is dependent on the gene context of the 
repeat; the brain regions first affected by each disease vary as do the threshold number of repeats needed 
to cause disease. With the exception of X-linked spinobulbar muscular atrophy, which is caused by a 
CAG expansion in the coding region of the androgen receptor[4], all are autosomal dominant in 
inheritance. Spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7, and 17 are caused by CAG repeat expansions in 
the ataxin 1, 2, 3, 6, 7, and TBP genes and affect primarily the cerebellum and brainstem; dentatorubral-
pallidoluysian atrophy is caused by a CAG repeat expansion in the atrophin 1 gene and affects the 
cerebellum as well as the cortex and midbrain[5,6,7,8].  
The gene responsible for HD was identified in 1993 and codes for a widely expressed 348-kDa 
protein with a polymorphic CAG trinucleotide repeat[9]. The CAG repeats translate into a homomeric 
polyglutamine (polyQ) stretch in the amino terminus of the huntingtin (htt) protein. HD develops when 
the polyQ stretch exceeds a threshold of 36 glutamines. The length of the polyQ stretch is inversely 
proportional to the age of onset of the disease; polyQ stretch length may explain more than 70% of the 
variation in the age of disease onset[10,11,12,13] and can be used in a parametric model to predict disease 
incidence accurately[14]. 
SELECTIVE NEURONAL DEATH 
As HD progresses, mutant htt leads to the death of specific neuronal subpopulations. Medium spiny 
neurons in the striatum that express enkephalin and γ-aminobutyric acid are particularly susceptible to 
mutant htt[15]. The medial paraventricular region and tail of the caudate, along with the dorsal putamen, 
are the first brain regions to show significant atrophy[16]. Neuronal death spreads to the cortex, white 
matter, and thalamus later in the disease[17,18]. Although htt is widely expressed in the brain and other 
tissues[19,20], the level of expression varies by brain region and cell type. This variation may explain part 
of the specificity of cell death in HD[21]. 
GAIN OF TOXIC FUNCTION 
The genetics of HD and other CAG repeat disorders strongly support the hypothesis that polyQ expansion 
leads to a toxic activity that is not present for shorter polyQ stretches. HD is inherited in an autosomal-
dominant pattern with almost complete penetrance when the gene contains more than 40 CAG 
repeats[14]. In mice, the deletion of Hdh, the mouse HTT homolog, results in embryonic lethality[22,23]. 
While supporting the possibility that the normal function of htt is required during brain development, this 
loss-of-function phenotype is quite distinct from that seen in HD[24]; furthermore, mutant htt is sufficient 
to rescue the embryonic-lethal loss-of-function phenotype, arguing that mutant htt retains significant 
activity and that mutant htt–induced pathology is distinct from a loss-of-function phenotype[25]. Cell-
specific inactivation of Hdh in the brain and testis of mice results in age-related neurodegeneration, but 
neither the pathology nor the phenotype resembles HD models[26]. In contrast, a fragment of mutant htt 
composed of only the first exon is sufficient to cause a progressive neurodegenerative phenotype 
resembling HD[27]. Similarly, a long polyQ expansion in the context of full-length htt in mice results in 
behavioral changes and neuropathology characteristic of HD[28,29]. 
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HTT INCLUSION BODIES ARE A HALLMARK OF HD 
Accompanying the gain of toxic function, full-length mutant htt is cleaved into amino-terminal fragments 
that are deposited in large, microscopically visible, inclusion bodies (IBs) in the nucleus, cytoplasm, and 
processes of neurons[30,31]. IBs form in populations of neurons in humans and mice that undergo death 
and dysfunction in the course of disease[30,31,32]. The formation of large, microscopically visible, 
intracellular aggregates is not unique to HD; the pathology of other diseases caused by polyQ expansion 
is also marked by the formation of IBs by each of the respective causative proteins.  
IB formation in polyQ diseases is mediated, at least in part, by the polyQ expansion itself[33], but 
other proteins are also present in these structures. Many components of the intracellular machinery 
responsible for handling and degrading misfolded protein, including chaperones, ubiquitin, proteasome 
subunits, and autophagic machinery, can be found in mutant htt IBs[30,31,34,35,36]. The colocalization 
of these proteins was one of the first clues that the regulation of intracellular mutant htt levels is central to 
HD pathogenesis.  
HD PATHOLOGY IS REVERSIBLE 
Even stronger evidence for the role of intracellular levels of mutant htt in HD pathogenesis comes from 
studies of an inducible mouse model of HD[37,38]. This model demonstrates neuropathology and 
behavioral changes characteristic of HD when the mutant htt transgene is expressed. If the transgene is 
shut off rather than remaining expressed after an initial period of induction, the decrease in burden of 
mutant htt leads to a decrease in the number of IBs, a decrease in brain atrophy, and an improvement in 
the motor phenotype of the mice. This reversal was dependent on the function of one major pathway for 
intracellular protein degradation, the ubiquitin-proteasome pathway (UPP). These results offered the 
possibility that UPP function might suppress mutant htt toxicity and that intracellular protein degradation 
may be impaired in the course of disease. Although these results also suggested that reducing IB 
formation would improve mutant htt toxicity, the relationship between IBs and HD pathogenesis has 
proved to be more complex (Fig. 1). 
 
FIGURE 1. A model of HD pathogenesis. HD is initiated by the expansion of a CAG stretch in the HD gene that codes for a polyQ stretch 
in the amino terminus of the htt protein (A). Chaperones, such as Hsp40 and Hsp70, regulate the folding of nascent polypeptides (B) and 
regulate the folding of mutant htt (C). The amount of intracellular mutant htt, likely of a particular conformation, predicts both neuronal 
toxicity (D) and IB formation (E). Since cells with IBs survive better than those without, it is likely that IB formation is a protective cellular 
response and unrelated to the primary mechanism by which mutant htt is toxic. 
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MUTANT HTT, IBs, AND TOXICITY 
Although many manipulations of yeast, mammalian cell culture, and transgenic mouse models show a 
correlation between IB formation and toxicity, an accumulating body of evidence demonstrates that IB 
formation is not necessary for htt toxicity and may instead be a protective cellular response. IB formation 
and toxicity both increase as a result of increasing expression of mutant htt protein, heat shock of cells, or 
by inhibiting chaperone function[39,40,41], while they decrease from decreasing mutant htt expression, 
overexpressing chaperones, activation of the IGF-1/Akt pathway, or overexpression of intracellular 
protein degradation machinery[42,43,44,45]. The presence of mutant htt IBs, however, can be dissociated 
from mutant htt toxicity. Low levels of transgene expression in mice expressing a yeast artificial 
chromosome encoding full-length mutant htt with 72 glutamines is sufficient for neuropathology with no 
IBs present[46]. In a primary neuronal culture system, cells that form mutant htt IBs survive better than 
those that do not. Instead, the amount of mutant htt on an individual cell basis predicts how long the cells 
will survive[47].  
To better understand the mechanism by which mutant htt levels may mediate HD pathogenesis, a 
closer examination of intracellular protein turnover is warranted. The literature supporting the role of 
autophagy in HD and neurodegeneration was recently reviewed[48,49]. We will focus on the role of the 
UPP in HD pathogenesis here. 
POLYUBIQUITIN CHAINS MARK PROTEINS FOR DEGRADATION 
The UPP is the major pathway for regulated intracellular protein degradation (Fig. 2). Proteins are tagged 
for degradation by the conjugation of a minimum of four ubiquitins in a polyubiquitin chain[50]. 
Ubiquitin, a 76-amino-acid polypeptide, is first activated and then conjugated by sequential ATP-
dependent thioester linkages to cysteine residues on E1 ubiquitin–activating enzymes and E2 ubiquitin–
conjugating enzymes[51]. With the assistance of an E3 ubiquitin ligase, ubiquitin forms an isopeptide 
bond with the side-chain amino group of lysine residues on substrate proteins[52,53,54]. Several internal 
lysine residues within ubiquitin can then be used as sites for additional ubiquitin conjugation: chain 
elongation through K48 is the canonical signal for protein degradation[50]. For some substrates, an E4 
ubiquitin chain elongation factor may enhance the efficiency of polyubiquitin chain formation[55,56]. 
Ubiquitin conjugation is in competition with other modifications of substrate lysines and in 
opposition to the activity of deubiquitinating enzymes. Modifications, such as the addition of the small 
ubiquitin-like modifier-1 (SUMO-1), can shunt proteins away from the UPP[57]. Deubiquitinating 
enzymes, which are predominantly cysteine proteases, play critical roles in processing ubiquitin 
precursors and removing ubiquitins from protein substrates[58,59]. While an increase in deubiquitination 
activity and the removal of ubiquitin from substrates early in the targeting process may delay or prevent 
protein degradation, a decrease in deubiquitinating activity may also decrease protein degradation by 
reducing the pool of free ubiquitin intracellularly[60]. 
PROTEASOMES DEGRADE POLYUBIQUITINATED SUBSTRATES 
Once proteins are polyubiquitinated, they are delivered to the proteasome for degradation. The 26S 
proteasome is a multisubunit complex composed of 19S regulatory and 20S core particles[61]. The 20S 
core is a cylindrical structure composed of four stacked heteroheptameric ring complexes. Subunits with 
trypsin-like, chymotrypsin-like, and peptidylglutamyl peptide hydrolase activities are contained in the two 
inner rings[62,63]. These activities are derepressed when the 20S core is bound by ATP-hydrolyzing 
subunits of the 19S regulatory particle[64,65]. The 19S particle binds to polyubiquitin chains on 
degradation substrates, releases ubiquitins, and unfolds and translocates substrates into the central 
chamber of the 20S core[61,62]. In some cases, the 11S regulatory particle, alternatively designated REG  
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FIGURE 2. The UPP. Ubiquitin (Ub) is activated by conjugation to an E1 ubiquitin–activating enzyme and 
transferred to an E2 ubiquitin–conjugating enzyme, which in concert with an E3 ubiquitin ligase, transfers ubiquitin 
to a target lysine on a substrate protein. Additional ubiquitins can be added to the already conjugated ubiquitin, 
resulting in a polyubiquitin chain. Once a polyubiquitin chain formed by sequential lysine 48 linkages is conjugated 
to a target, the substrate is degraded by the 26S proteasome. The 19S regulatory cap binds the polyubiquitin chain, 
removes the ubiquitins, unfolds the substrate, and activates the 20S proteolytic core in an ATP-dependent manner. 
The 11S regulatory complex performs an analogous role to the 19S complex, but in a ubiquitin and ATP-independent 
fashion. The 20S core is organized in four heptameric rings, with tryptic, chymotryptic, and peptidylglutamyl 
proteolytic activities contained in the inner β rings. Peptides released by the proteasome may be further degraded by 
intracellular peptidases. 
or PA28, substitutes for the 19S complex and leads to changes in substrate preference and proteolytic 
activity[66,67,68,69,70]. In contrast to activation by the 19S particle, PA28 activation of the 20S core is 
ATP independent, and PA28 mediates ubiquitin-independent protein degradation. This activity may be 
particularly important for the degradation of small peptide fragments[71,72]. 
TARGETING MUTANT HTT TO THE UPP 
Ubiquitin and mutant htt colocalize in brain tissue from HD patients[30,73], HD mouse models[31], and 
HD cellular models[74,75]. Biochemical analysis demonstrates that ubiquitin is present in mutant htt 
IBs[34,76] and that mutant htt is itself ubiquitinated[75,77,78]. Ubiquitination of mutant htt is in 
competition with modification by SUMO-1, which reduces IB formation and exacerbates mutant htt 
toxicity[78]. Polyubiquitinated mutant htt is targeted to the proteasome for degradation (Fig. 3). After 
proteasome inhibition, ubiquitinated species of mutant htt accumulate, and the amount of aggregated 
mutant htt increases[75,77,79,80,81].  
The machinery responsible for ubiquitinating specific substrates in mammalian systems has been 
difficult to identify, and the case of mutant htt is no different. There are more than 50 E2-conjugating 
enzymes and over 500 E3 ligases in the human genome[82]. Much of the substrate specificity for 
ubiquitination has been ascribed to E3 ligases, although the determinants of specificity are poorly 
understood. The challenge of identifying the ligase that ubiquitinates a particular protein substrate is akin 
to that of identifying a kinase responsible for phosphorylating a particular target — functional 
compensation muddles the interpretation of genetic approaches, and functional redundancy leads to 
difficulties in interpreting experiments from reconstituted systems. 
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FIGURE 3. Mutant htt and the UPP. The ubiquitination and 
degradation of mutant htt by the proteasome decreases neuronal 
dysfunction and death in cellular and animal models of HD. 
However, mutant htt impairs UPP function, with an 
accompanying intracellular accumulation of ubiquitinated 
proteins. The impairment of UPP function may lead to toxicity 
by an increase in the amount of intracellular mutant htt, an 
increase in the levels of other proteins targeted for degradation, 
or a combination thereof. Although cells with IBs show high 
levels of UPP impairment, and ubiquitin and some proteasome 
subunits localize to IBs, UPP impairment can occur 
independently of IB formation. Interestingly, while proteasome 
subunits are recruited to actively forming IBs, preformed IBs in 
vitro do not have this activity. Although it is hard to reconcile 
high levels of UPP impairment with improved survival in cells 
with mutant htt IBs, one possibility is that IB formation may be 
one mechanism by which the cell may improve the degradation 
of other cellular proteins (gray lines with htt IB formation and 
black lines with htt flux through the UPP). 
Although determining what machinery is physiologically responsible for the degradation of mutant 
htt has not yet been possible, UPP components that affect the ubiquitination, degradation, and toxicity of 
mutant htt have been identified. hE2-25K, a ubiquitin-conjugating enzyme, interacts with the first 540 
amino acids of mutant htt[83], increases mutant htt IB formation, and decreases toxicity in cell 
culture[84]. A dominant-negative form of another E2, cdc34, decreases the number of IBs in cell culture 
and potentiates neuronal death due to mutant htt[74]. When overexpressed, the E3 ubiquitin ligase Hrd1 is 
found in complexes with htt, increases the amount of ubiquitinated mutant htt, and decreases the total 
amount of mutant htt in cell culture. Hrd1 overexpression also decreases the number of mutant htt IBs and 
mutant htt toxicity[85]. The E3 ubiquitin ligase parkin colocalizes with mutant htt in the brains of HD 
Mitra and Finkbeiner: The Ubiquitin-Proteasome Pathway in HD TheScientificWorldJOURNAL (2008) 8, 421–433
 
 427
patients and HD mouse models. Parkin reduces the levels of polyQ-containing proteins through its 
ubiquitin ligase activity[45]. The E4 protein CHIP colocalizes with mutant htt and, when overexpressed, 
increases mutant htt ubiquitination, decreases IB formation, and improves survival in a cellular model of 
HD[86]. Loss of Ubp13, the yeast homolog of the human deubiquitinating enzyme Usp12, enhances 
mutant htt toxicity in yeast[87].  
While these results demonstrate that the UPP can degrade mutant htt and modulate htt toxicity, the 
roles of hE2-25K, cdc34, Hrd1, parkin, CHIP, and Usp12 in HD pathogenesis remain unclear. These 
genes may modulate mutant htt IB formation and toxicity by a direct effect on mutant htt ubiquitination, 
an effect on the ubiquitination of other substrates, or an effect on the activity or intracellular localization 
of interaction partners. No matter the mechanism, the result of these effects is consistent with the 
ubiquitination of mutant htt enhancing mutant htt degradation and reducing mutant htt toxicity (Fig. 3). 
MUTANT HTT IMPAIRS UPP FUNCTION 
The hypothesis that the polyQ expansion in mutant htt impairs UPP function originated from the 
observation that components of the UPP are stably associated with mutant htt in IBs. While IBs in other 
neurodegenerative diseases, such as SCA1 or ALS, have a fast component of protein exchange between 
IBs and the cellular milieu[88,89,90], IBs with mutant htt appear to be largely static in cell culture. 
Eukaryotic proteasomes degrade polyQ sequences poorly in reconstituted systems[91,92] and may release 
polyQ peptides for further degradation by cytosolic aminopeptidases[93]. These results have led to the 
hypothesis that polyQ peptides may be transiently retained in the proteolytic core and impair proteasome 
activity, but it is equally possible that the propensity for mutant htt to aggregate may lead to difficulties 
with targeting mutant htt to the proteasome or for the proteasome regulatory complex to unfold mutant htt 
and present it to the core catalytic subunits for proteolysis.  
Mutant htt impairs the ability of the UPP to degrade other intracellular protein substrates, but this 
effect is not likely due to the recruitment of UPP components into static IBs (Fig. 3)[94,95,96]. Although 
UPP machinery colocalizes with htt IBs, the majority of proteasome subunits are not recruited to these 
structures in cell culture models[95]. While the accumulation of proteasome substrates is pronounced in 
cells with mutant htt IBs[94], UPP impairment occurs without IB formation[95]. 
By impairing UPP function, mutant htt establishes an unstable equilibrium that may underlie HD 
pathogenesis. As mutant htt causes UPP substrates to accumulate, mutant htt levels increase and worsen 
UPP impairment. In response to increasing levels of UPP impairment, the cell may deliver substrates to 
the autophagic pathway of intracellular protein degradation through mediators, such as HDAC6[97], and 
attempt to reestablish cellular homeostasis[48]. 
MEDIATORS OF UPP IMPAIRMENT IN HD 
While mutant htt clearly impairs UPP function, the role of this impairment in HD has yet to be elucidated. 
UPP impairment may have potentially subtle changes on a large number of proteins, complicating the 
identification of effectors of UPP dysfunction. Mutant htt and other proteins prone to misfold may 
establish positive feedback circuits for UPP impairment and cellular dysfunction[98]. The interaction of 
these substrates may be indirect and coordinated by chaperones. Protein interaction partners may also 
modulate reciprocal, metastable, conformational changes in protein structure akin to prion conversion 
through interaction domains, such as polyQ stretches[99]. These conformational changes may promote or 
inhibit cellular dysfunction and death. 
Inhibition of the proteasome in proliferating cells causes cell-cycle arrest and ensuing cell death. If 
UPP impairment leads to toxicity through an accumulation of toxic protein, potential mediators include 
Rb, p53, E2F, p21, p27, cyclin D, cyclin E[100], BIK, NOXA, BIM[101], and AIF[102]. The 
relationships among these substrates, UPP function, and cellular toxicity in postmitotic cells are unclear. 
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One intriguing potential mediator of UPP impairment is a mutant form of ubiquitin-B (UBB+1). 
UBB+1 is found in a wide range of diseases, including Alzheimer’s disease[103] and polyQ 
diseases[104], and demonstrates a dose-dependent conversion between UPP substrate and UPP 
inhibitor[105]. UBB+1 is a particularly attractive candidate for the role of a molecular switch that could 
induce cell death and prevent the accumulation of a large burden of insoluble, aggregated protein. 
UPP function is critical for the maintenance of long-term potentiation (LTP)[106] and for regulating 
protein synthesis[107] in neurons. A careful analysis relating UPP impairment and LTP or protein 
synthesis may be fruitful to understand early neuronal dysfunction in the course of HD. 
UPP FUNCTION AND AGING 
The dependence of neurodegenerative disease on age may partially be explained by the combination of an 
increased burden of misfolded protein and a decline in UPP function. As HD mice age, nuclear and 
cytoplasmic proteasome activities decline in the cortex, striatum, and cerebellum[80]. An increased 
proportion of cross-linked or oxidized proteasome subunits may accompany the aging process[108]. 
Intriguingly, the function of an E3 ubiquitin ligase in C. elegans regulates longevity[109], offering the 
possibility that UPP function may affect neurodegenerative disease by changing the rate of aging. Further 
investigation into the interaction between age and UPP function will help to determine if UPP impairment 
contributes to the age dependence of HD. 
THERAPEUTIC STRATEGIES AND FUTURE DIRECTIONS 
Although the identity of the UPP machinery responsible for degrading mutant htt remains unclear, the 
UPP likely plays a central role in HD pathogenesis. UPP impairment is well documented in the 
pathogenesis of neurodegenerative disease. Mutations in the E3 ubiquitin ligases parkin and E6-AP cause 
Parkinson’s disease and Angelman’s syndrome, respectively, while mutations in the ubiquitin protease 
ataxin-3 cause Machado-Joseph’s disease[110,111,112,113,114]. In each of these diseases, a decrease in 
the activity of a particular UPP component leads to the dysfunction and death of particular subsets of 
neurons.  
Improving the function of the UPP may be one approach to prevent the progression of HD and 
neurodegenerative disease generally. However, strategies to increase UPP function will have a multitude 
of off-target effects unless the machinery specifically responsible for the turnover of particular mutant 
proteins is targeted.  
Molecular links between UPP impairment and HD pathogenesis have yet to be identified. Some of 
this machinery must have cell type–specific activity if the neuronal specificity of cell death in HD is 
explained by UPP impairment. The relative contribution of the UPP and the autophagic pathway in the 
turnover of mutant htt will also be important to determine. The efficacy of strategies to treat HD that 
improve UPP function will likely be dependent on the strength of the relationship between UPP 
impairment and HD pathogenesis. 
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